发明申请
US20090123421A1 ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
审中-公开
作为抗肿瘤剂的抗-LYMPHOTOXIN-BETA受体抗体
- 专利标题: ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
- 专利标题(中): 作为抗肿瘤剂的抗-LYMPHOTOXIN-BETA受体抗体
-
申请号: US12262794申请日: 2008-10-31
-
公开(公告)号: US20090123421A1公开(公告)日: 2009-05-14
- 发明人: Jeffrey L. Browning , Werner Meier , Christopher D. Benjamin
- 申请人: Jeffrey L. Browning , Werner Meier , Christopher D. Benjamin
- 申请人地址: US MA Cambridge
- 专利权人: Biogen Idec MA Inc.
- 当前专利权人: Biogen Idec MA Inc.
- 当前专利权人地址: US MA Cambridge
- 主分类号: A61K38/21
- IPC分类号: A61K38/21 ; A61K39/395 ; C12Q1/02 ; C07K16/18 ; A61K38/16
摘要:
This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
信息查询
IPC分类: